XBiotech (XBIT) & Its Competitors Financial Contrast

XBiotech (NASDAQ: XBIT) is one of 289 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare XBiotech to related businesses based on the strength of its analyst recommendations, earnings, valuation, profitability, institutional ownership, risk and dividends.

Profitability

This table compares XBiotech and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XBiotech N/A -60.07% -55.80%
XBiotech Competitors -5,441.68% -162.70% -35.92%

Analyst Ratings

This is a summary of recent recommendations for XBiotech and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech 0 1 1 0 2.50
XBiotech Competitors 1134 3426 11925 240 2.67

XBiotech currently has a consensus target price of $13.00, indicating a potential upside of 212.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.55%. Given XBiotech’s higher probable upside, analysts plainly believe XBiotech is more favorable than its competitors.

Valuation & Earnings

This table compares XBiotech and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
XBiotech N/A -$52.76 million -2.55
XBiotech Competitors $290.27 million $35.99 million 59.94

XBiotech’s competitors have higher revenue and earnings than XBiotech. XBiotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

XBiotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, XBiotech’s competitors have a beta of 0.80, suggesting that their average stock price is 20% less volatile than the S&P 500.

Insider & Institutional Ownership

11.0% of XBiotech shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 35.7% of XBiotech shares are held by company insiders. Comparatively, 17.4% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

XBiotech competitors beat XBiotech on 8 of the 12 factors compared.

XBiotech Company Profile

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply